Esperion Therapeutics ESPR Prepaid clinical development costs
Prepaid clinical development costs at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:PrepaidClinicalDevelopmentCostsCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's prepaid clinical development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's prepaid clinical development costs?
- Esperion Therapeutics (ESPR) reported prepaid clinical development costs of $5.79M in Q1 2026.
- How has Esperion Therapeutics's prepaid clinical development costs changed year-over-year?
- Esperion Therapeutics's prepaid clinical development costs increased by 1049.0% year-over-year, from $504K to $5.79M.
- What is the long-term trend for Esperion Therapeutics's prepaid clinical development costs?
- Over 5 years (2020 to 2025), Esperion Therapeutics's prepaid clinical development costs has grown at a 36.8% compound annual growth rate (CAGR), from $844K to $4.04M.
- What does prepaid clinical development costs mean?
- This represents payments made in advance to third-party research organizations or clinical sites for upcoming drug development activities. It reflects the company's commitment to future R&D pipelines and serves as a leading indicator of planned clinical trial activity. Monitoring this helps investors gauge the near-term cash outflow requirements for ongoing pharmaceutical research.